Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article (105)

Advertisement

Research Article Free access | 10.1172/JCI110704

Differential Action of the Bisphosphonates (3-Amino-1-Hydroxypropylidene)-1,1-Bisphosphonate (APD) and Disodium Dichloromethylidene Bisphosphonate (Cl2MDP) on Rat Macrophage-mediated Bone Resorption In Vitro

Pieter H. Reitsma, Steven L. Teitelbaum, Olav L. M. Bijvoet, and Arnold J. Kahn

Department of Clinical Endocrinology, University Hospital, Leiden, The Netherlands

Department of Pathology and Laboratory Medicine, The Jewish Hospital of St. Louis, St. Louis, Missouri 63110

Division of Bone and Mineral Metabolism, The Jewish Hospital of St. Louis, St. Louis, Missouri 63110

Washington University Schools of Medicine and Dental Medicine, St. Louis, Missouri 63110

Find articles by Reitsma, P. in: JCI | PubMed | Google Scholar

Department of Clinical Endocrinology, University Hospital, Leiden, The Netherlands

Department of Pathology and Laboratory Medicine, The Jewish Hospital of St. Louis, St. Louis, Missouri 63110

Division of Bone and Mineral Metabolism, The Jewish Hospital of St. Louis, St. Louis, Missouri 63110

Washington University Schools of Medicine and Dental Medicine, St. Louis, Missouri 63110

Find articles by Teitelbaum, S. in: JCI | PubMed | Google Scholar

Department of Clinical Endocrinology, University Hospital, Leiden, The Netherlands

Department of Pathology and Laboratory Medicine, The Jewish Hospital of St. Louis, St. Louis, Missouri 63110

Division of Bone and Mineral Metabolism, The Jewish Hospital of St. Louis, St. Louis, Missouri 63110

Washington University Schools of Medicine and Dental Medicine, St. Louis, Missouri 63110

Find articles by Bijvoet, O. in: JCI | PubMed | Google Scholar

Department of Clinical Endocrinology, University Hospital, Leiden, The Netherlands

Department of Pathology and Laboratory Medicine, The Jewish Hospital of St. Louis, St. Louis, Missouri 63110

Division of Bone and Mineral Metabolism, The Jewish Hospital of St. Louis, St. Louis, Missouri 63110

Washington University Schools of Medicine and Dental Medicine, St. Louis, Missouri 63110

Find articles by Kahn, A. in: JCI | PubMed | Google Scholar

Published November 1, 1982 - More info

Published in Volume 70, Issue 5 on November 1, 1982
J Clin Invest. 1982;70(5):927–933. https://doi.org/10.1172/JCI110704.
© 1982 The American Society for Clinical Investigation
Published November 1, 1982 - Version history
View PDF
Abstract

The bisphosphonates (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) and disodium dichloromethylidene bisphosphonate (Cl2MDP) effectively inhibit the accelerated bone resorption associated with some skeletal disorders, e.g., Paget's disease. However, it has not been established whether these compounds exert their inhibitory effect by rendering the bone mineral more resistant to degradation, by diminishing the activity of resorbing cells, or through some combination of both activities. In this study, we have tested these possibilities using an in vitro resorption assay system consisting of elicited rat peritoneal macrophages co-cultured with particles of 45Ca-labeled, devitalized rat bone. This assay system permits the quantitative assessment of the action of APD and Cl2MDP on the two major phases of bone resorption (cell-substrate attachment and osteolysis) under circumstances where the drugs are present continuously or, most importantly for the issues in question, after the separate pretreatment of the particles or the resorbing cells.

Our data indicate that (a) Both APD and Cl2MDP at concentrations ≥5 × 10-6 M diminish macrophage-mediated 45Ca release (i.e., bone resorption) in a log dose-dependent fashion. (b) A 10-min pretreatment of bone particles with either bisphosphonate (P-C-P) similarly inhibits resorptive activity, but is most pronounced with Cl2MDP. However, only APD is effective in reducing resorption when cells are preincubated (for 24 h) with P-C-P. (c) In cultures containing both labeled and unlabeled bone, significant inhibition occurs only when the labeled particles are coated with P-C-P (indicating that the action of P-C-P-treated bone is highly localized). (d) P-C-P does not diminish cell-bone particle attachment, an essential step in the resorptive process. On the other hand, delaying the addition of P-C-P until after cell-bone attachment is completed significantly reduces the resorption-inhibiting effect of these compounds. (e) Cl2MDP reduces culture DNA content in proportion to its inhibitory effect on resorption, and both the inhibitory and cytotoxic actions of this P-C-P are dependent upon the presence of bone. On the other hand, APD is cytotoxic only at very high concentrations (10-4 M), acts independently of the presence of bone, and inhibits resorption without killing cells.

We conclude that the mechanisms of action of APD and Cl2MDP are markedly different. Cl2MDP is a potent cytotoxin in the presence of bone and apparently exerts its inhibitory effect in this manner. APD is noncytotoxic at levels adequate to suppress resorption and, therefore, must inhibit macrophage activity by some other mechanism. Neither P-C-P appears to limit resorption by decreasing the solubility of mineralized bone matrix.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 927
page 927
icon of scanned page 928
page 928
icon of scanned page 929
page 929
icon of scanned page 930
page 930
icon of scanned page 931
page 931
icon of scanned page 932
page 932
icon of scanned page 933
page 933
Version history
  • Version 1 (November 1, 1982): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article (105)

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts